What the Two Boxed Warnings Require
The prescribing information for the newly approved ADHD medication Simtriyo carries two boxed warnings, the strongest safety labeling the FDA applies, and one of them requires monitoring of every child who takes it.
The FDA approved Simtriyo, generic name centanafadine, on July 24 for adults and children aged 6 and older weighing at least 20 kilograms, roughly 44 pounds. The prescribing information released by Otsuka Pharmaceutical sets out the safety requirements that will govern prescribing.
The first boxed warning concerns suicidal ideation and behaviors. Higher rates occurred in treated patients aged 6 to 12 than in those receiving placebo. The label instructs prescribers to "closely monitor all pediatric patients for suicidal ideation and behaviors," and to consider stopping the medication in patients who develop them.
Two points of proportion belong here rather than further down. The elevated rates were observed in the 6 to 12 age group, but the monitoring instruction covers all pediatric patients, not just that age range. And the events were uncommon in absolute terms, with two reported incidents among children receiving the drug compared with none on placebo. A boxed warning signals that a risk requires active attention, not that it is likely.
The second boxed warning addresses abuse, misuse and addiction. The label states that misuse and abuse of central nervous system stimulants can lead to overdose and death, and directs prescribers to assess each patient's risk before prescribing, to counsel families on secure storage and proper disposal, and to reassess and monitor for signs of misuse throughout treatment.
Why the Controlled Substance Status Matters
The label describes Simtriyo as a norepinephrine, dopamine, and serotonin reuptake inhibitor and a central nervous system stimulant. Otsuka has said it will be commercially available later this year, following scheduling by the Drug Enforcement Administration.
This is the detail most likely to reshape family expectations, and it corrects a common early framing of the drug as a non-stimulant alternative. Because the label classifies it as a CNS stimulant and DEA scheduling is pending, households should not assume the medication will avoid the controlled substance requirements that have made stimulant prescriptions difficult to manage in recent years.
Existing stimulant medications for ADHD are Schedule II, which carries monthly prescribing limits and has contributed to pharmacy shortages. Where Simtriyo lands has not been announced. Until the DEA acts, no one can say whether it will involve the same refill constraints, and families switching specifically to escape those constraints should wait for that determination.
MedicalDaily previously reported on who qualifies under the new label and how the drug differs from existing options, noting that the prescribing information is the authoritative source for the complete safety profile. That information is now available, and it changes the practical picture in two ways: the boxed warnings impose monitoring duties, and the stimulant classification affects access.
What Else the Label Tells Prescribers to Monitor
Beyond the boxed warnings, the prescribing information sets out several ongoing checks that families will encounter at follow-up visits.
Prescribers are told to assess heart rate and blood pressure after each dose increase and periodically during treatment, and to avoid the medication in patients with known structural cardiac abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease or other serious cardiac disease. For children, the label directs clinicians to closely monitor height, body mass index and linear growth, and to consider interrupting treatment in a child not growing or gaining as expected.
The label also flags serious hypersensitivity reactions including anaphylaxis and angioedema, new psychotic or manic symptoms, peripheral vasculopathy including Raynaud's phenomenon with attention to changes in the fingers and toes, serotonin syndrome when combined with other serotonergic drugs, and the emergence or worsening of tics or Tourette's syndrome.
The most common side effects were rash and decreased appetite in children aged 6 to 12; decreased appetite, nausea, rash, headache and abdominal pain in adolescents; and headache, decreased appetite, insomnia, nausea, dry mouth and diarrhea in adults.
Approval rested on four randomized, double-blind, placebo-controlled trials in children, adolescents and adults, with symptom improvements reported as early as week one. Those trials measured outcomes over roughly six weeks, so they describe short-term response rather than durability over the years many patients take ADHD medication.
Who Should Not Take It
The label lists three contraindications. The medication should not be used in patients with known hypersensitivity to centanafadine or its ingredients, in patients taking or within 14 days of stopping a monoamine oxidase inhibitor, or in patients with pheochromocytoma or a history of it.
The label separately states that use is not recommended in children younger than 6, because that group showed a higher incidence of weight loss, or in children weighing less than 20 kilograms, citing a lack of data and the risk of weight loss.
Anyone taking an antidepressant or another medication affecting serotonin should raise that specifically with the prescriber, given the serotonin syndrome warning. Pregnant patients and their clinicians are encouraged to contact the National Pregnancy Registry for ADHD Medications at 1-866-961-2388.
Dr. Lenard A. Adler, who directs the adult ADHD program at NYU Langone Health, said in the manufacturer's announcement that "ADHD is a highly individualized condition and treatment decisions should reflect" each patient's needs. Otsuka chief medical officer John Kraus described the approval as introducing "a novel treatment approach for this condition," a characterization from the company that has not been independently evaluated against existing treatments.
What Families Should Ask Before the Launch
The medication is not yet available, which gives families time to prepare rather than decide quickly.
Parents considering it for a child should ask the prescriber what the monitoring plan will look like in practice, specifically how often blood pressure, heart rate, and growth will be checked, and what changes in mood or behavior should prompt a call rather than waiting for the next appointment. Ask what the plan is if appetite decreases.
Families should also ask about secure storage before the first prescription, since the label directs clinicians to counsel on storage and disposal. Adults with a personal or family history of substance use disorder should raise it directly.
No one should stop a current ADHD medication in anticipation of switching, and no one should start, stop or change any medication based on a news article. Those decisions belong to the prescribing clinician.
If a child or adult taking any ADHD medication expresses thoughts of self-harm, contact the prescribing clinician promptly, and seek urgent care for immediate safety concerns. In the United States, the 988 Suicide and Crisis Lifeline is available by call or text.
The confirmed facts are the two boxed warnings, the monitoring requirements and the stimulant classification. The families most affected are those with children aged 6 to 12 who are considering this medication. The reasonable next step is a conversation about the monitoring plan. The central uncertainty is the DEA schedule, which will determine how easily prescriptions can be filled. The next expected development is that scheduling decision, ahead of availability later this year.
Frequently Asked Questions
What is a boxed warning? The FDA's strongest labeling, used to flag risks serious enough to require active clinician attention. It does not mean the risk is likely.
Which children need suicidality monitoring? The label instructs prescribers to monitor all pediatric patients, though the higher rates were observed in the 6 to 12 age group.
How common were these events? Uncommon. Two incidents were reported among children receiving the drug, compared with none among those on placebo.
Is Simtriyo a stimulant? The label describes it as a central nervous system stimulant. DEA scheduling has not been completed.
When will it be available? Otsuka has said later this year, after DEA scheduling. No date has been announced.
Who should not take it? Patients with hypersensitivity to it, those taking or recently stopping a monoamine oxidase inhibitor, and those with pheochromocytoma or a history of it.
What should parents watch for at home? Changes in mood or behavior, appetite loss, and growth concerns. Ask the prescriber which changes warrant a call rather than waiting for the next visit.
